6021^ Background: The EXTREME trial demonstrated that patients with R/M-SCCHN benefit
significantly from the addition of cetuximab to first-line platinum-based CT in relation to …

The major development of the past decade in the first-line treatment of recurrent and/or
metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) was the …

Importance There remains an unmet need to improve clinical outcomes in patients with
recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) …

Background Patients with R/M SCC have low response rates to second line therapies,
including PD-1 inhibitors nivolumab and pembrolizumab, representing an area of unmet …

PURPOSE Pembrolizumab and pembrolizumab-chemotherapy demonstrated efficacy in
recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048. Post hoc …

Purpose: Cetuximab, which modulates immune responses, may affect the efficacy of
subsequent immunotherapy. Here, we assessed outcomes with nivolumab, by prior …

In the randomized, phase 3 CheckMate 141 trial, nivolumab significantly improved overall
survival (OS) versus investigator's choice (IC) of chemotherapy at primary analysis among …

Background Recurrent/metastatic squamous cell carcinoma of head and neck (R/M SCCNH)
is still a difficult-to-treat disease with poor clinical outcomes and limited treatment choices. In …

BACKGROUND Prognosis of recurrent or metastatic (R/M) head and neck squamous cell
carcinoma (HNSCC) remains poor. The addition of cetuximab, to platinum and fluorouracil …

Background: Treatment responses to immune checkpoint inhibitors may occur after initial
radiologic evidence of progression. In CheckMate 141 (NCT02105636), a randomized …